A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Inclusion criteria

• Have type 2 diabetes
• Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
• Have a BMI ≥ 27 kg/m2
• Have a stable body weight (<5% body weight change) for 90 days prior to screening

Exclusion criteria

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have type 1 diabetes
• Have taken any of the following antihyperglycemic medications within 90 days before screening:

• amylin analogs
• glucagon-like peptide-1 (GLP-1) receptor agonists
• glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
• insulin
• Have had within 90 days prior to screening:

• heart attack
• stroke
• coronary artery revascularization
• unstable angina, or
• hospitalization due to congestive heart failure
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening